Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sam Lim

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
The Lancet. Rheumatology|September 20, 2025
Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation studyJasvinder A Singh, Larry R Hearld, Seth Eisen, et al.
Immunity|January 16, 2020
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus ErythematosusScott A Jenks, Kevin S Cashman, Esther Zumaquero, et al.
Immunity|October 14, 2018
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus ErythematosusScott A Jenks, Kevin S Cashman, Esther Zumaquero, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Arthritis Care & Research|January 24, 2023
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate ModelingAnn E Clarke, John G Hanly, Murray B Urowitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception CohortJohn G Hanly, Caroline Gordon, Sang-Cheol Bae, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 17, 2023
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception CohortYann Nguyen, Benoît Blanchet, Murray B Urowitz, et al.
Lupus Science & Medicine|November 17, 2022
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquineCelline C Almeida-Brasil, John G Hanly, Murray Urowitz, et al.
Arthritis Care & Research|August 20, 2020
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and MedicationsSasha Bernatsky, Rosalind Ramsey-Goldman, Murray B Urowitz, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
The Lancet. Rheumatology|September 20, 2025
Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation studyJasvinder A Singh, Larry R Hearld, Seth Eisen, et al.
Immunity|January 16, 2020
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus ErythematosusScott A Jenks, Kevin S Cashman, Esther Zumaquero, et al.
Immunity|October 14, 2018
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus ErythematosusScott A Jenks, Kevin S Cashman, Esther Zumaquero, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Arthritis Care & Research|January 24, 2023
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate ModelingAnn E Clarke, John G Hanly, Murray B Urowitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception CohortJohn G Hanly, Caroline Gordon, Sang-Cheol Bae, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 17, 2023
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception CohortYann Nguyen, Benoît Blanchet, Murray B Urowitz, et al.
Lupus Science & Medicine|November 17, 2022
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquineCelline C Almeida-Brasil, John G Hanly, Murray Urowitz, et al.
Arthritis Care & Research|August 20, 2020
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and MedicationsSasha Bernatsky, Rosalind Ramsey-Goldman, Murray B Urowitz, et al.
Pageof 14